LZTR1 leucine zipper like post translational regulator 1
ENSG00000099949 · protein coding · Open Targets profile
Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates ubiquitination of Ras GTPases (M-Ras/MRAS, K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS) and Ras- like protein RIT1 (PubMed:30442762, PubMed:30442766, PubMed:30481304, PubMed:40934300). Acts as a negative regulator of RAS-MAPK signaling by controlling Ras levels and decreasing Ras association with membranes (PubMed:30442762, PubMed:30442766, PubMed:30481304, PubMed:40934300). {ECO:0000269|PubMed:30442762, ECO:0000269|PubMed:30442766, ECO:0000269|PubMed:30481304, ECO:0000269|PubMed:40934300}.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- PROTAC
- Database Ubiquitination, Half-life Data
gnomAD loss of function constraint: o/e 2.4588000774383545 (upper bound 2.7248001098632812). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
No named investigators on registry trials of LZTR1's approved or late-stage drugs in the last three years.
No terminated, withdrawn or suspended trials of LZTR1's drugs are registered
All 0 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.
| Drug | Type | Highest stage | Indications | Source records |
|---|---|---|---|---|
| No drugs or clinical candidates recorded. | ||||